MedTrace Logo

Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity

NCT00622726 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-06-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to determine the efficacy and additional advantages of intravitreal bevacizumab in the treatment of ROP for both Zone I and Zone II Posterior.

Conditions

  • Retinopathy of Prematurity

Interventions

DRUG

Bevacizumab

Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.

PROCEDURE

Conventional Laser for ROP

Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Helen A. Mintz-Hittner, M.D. · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
4 Weeks
Max Age
22 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-08-31
Completion
2020-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00622726 on ClinicalTrials.gov